样式: 排序: IF: - GO 导出 标记为已读
-
Emerging Treatments for Subarachnoid Hemorrhage CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2024-02-27 Matthew C. Findlay, Mrinmoy Kundu, Jayson R. Nelson, Kyril L. Cole, Candace Winterton, Samuel Tenhoeve, Brandon Lucke-Wold
: The current landscape of therapeutic strategies for subarachnoid hemorrhage (SAH), a significant adverse neurological event commonly resulting from the rupture of intracranial aneurysms, is rapidly evolving. Through an in-depth exploration of the natural history of SAH, historical treatment approaches, and emerging management modalities, the present work aims to provide a broad overview of the shifting
-
T Lymphocyte Interferon-gamma Response to Anaplasmataceae-related Major Surface Proteins and Ankyrin A in Fibromyalgia CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2024-02-20 Basant K. Puri, Rosemarie Preyer, Gary S. Lee, Armin Schwarzbach
Background: The aetiology of fibromyalgia is unknown; its symptoms may be related to a T-lymphocyte-mediated response to infectious organisms. Objectives: First, to test the hypothesis that fibromyalgia is associated with increased interferon (IFN)-γ-secreting T-lymphocytes after stimulation with Anaplasmataceae-related major surface proteins (MSFs) and the macromolecular translocation type IV secretion
-
Designing and Formulation of Nanocarriers for “Alzheimer’s and Parkinson’s” Early Detection and Therapy CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2024-02-14 Jakleen Abujamai, Rukhsana Satar, Shakeel Ahmed Ansari
: The potential of nanotechnology in advancing the diagnosis and treatment of neurodegenerative diseases is explored in this comprehensive literature review. Through an examination of various studies that utilize nanotechnology models. The aim of this paper is to evaluate whether these models can be considered a significant breakthrough in the field of neurodegeneration. The findings of these studies
-
Unraveling the Emerging Niche Role of Extracellular Vesicles (EVs) in Traumatic Brain Injury (TBI) CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2024-02-14 Sumel Ashique, Radheshyam Pal, Himanshu Sharma, Neeraj Mishra, Ashish Garg
: Extracellular vesicles or exosomes, often known as EVs, have acquired significant attention in the investigations of traumatic brain injury (TBI) and have a distinct advantage in actively researching the fundamental mechanisms underlying various clinical symptoms and diagnosing the wide range of traumatic brain injury cases. The mesenchymal stem cells (MSCs) can produce and release exosomes, which
-
The Possible Protective Effect of Taurine on Bisphenol: Induced Structural Changes on the Cerebral Cortex of Rats: Histological and Immunohistochemical Study CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2024-02-01 Samah Kandeel, Marwa M. Abd-Elsalam, Sherief Abd-Elsalam, Heba Hassan Elkaliny
Introduction: Bisphenol A (BPA) is a chemical compound that has been used in many industries, such as paints and dental sealants. Taurine is a semi-essential amino acid with antioxidant, anti-inflammatory, and anti-apoptotic actions. Aim: This study aimed to evaluate the possible protective effect of taurine on BPA-induced structural changes in the cerebral cortex of rats using histological and immunohistochemical
-
Application of Nanocomposites and Nanoparticles in Treating Neurodegenerative Disorders CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2024-01-29 Javeria Fatima, Yasir Hasan Siddique
: Neurodegenerative diseases represent a formidable global health challenge, affecting millions and imposing substantial burdens on healthcare systems worldwide. Conditions, like Alzheimer's, Parkinson's, and Huntington's diseases, among others, share common characteristics, such as neuronal loss, misfolded protein aggregation, and nervous system dysfunction. One of the major obstacles in treating
-
Non-coding RNAs as Key Regulators of the Notch Signaling Pathway in Glioblastoma: Diagnostic, Prognostic, and Therapeutic Targets CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2024-01-26 Seyed Hossein Shahcheraghi, Elmira Roshani Asl, Malihe Lotfi, Jamshid Ayatollahi, Seyed Hossein Khaleghinejad, Alaa A. Aljabali, Hamid A. Bakshi, Mohamed El-Tanani, Nitin Charbe, Ángel Serrano-Aroca, Vijay Mishra, Yachana Mishra, Rohit Goyal, Altijana Hromić-Jahjefendić, Vladimir N. Uversky, Marzieh Lotfi, Murtaza M. Tambuwala
: Glioblastoma multiforme (GBM) is a highly invasive brain malignancy originating from astrocytes, accounting for approximately 30% of central nervous system malignancies. Despite advancements in therapeutic strategies including surgery, chemotherapy, and radiopharmaceutical drugs, the prognosis for GBM patients remains dismal. The aggressive nature of GBM necessitates the identification of molecular
-
Potential Neuroprotective Role of Neurotrophin in Traumatic Brain Injury CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2024-01-26 Rei Shian Yap, Jaya Kumar, Seong Lin Teoh
: Traumatic brain injury (TBI) is a major global health issue that affects millions of people every year. It is caused by any form of external force, resulting in temporary or permanent impairments in the brain. The pathophysiological process following TBI usually involves excitotoxicity, mitochondrial dysfunction, oxidative stress, inflammation, ischemia, and apoptotic cell death. It is challenging
-
LRRK2; Communicative Role in the Treatment of Parkinson’s Disease and Ulcerative Colitis Overlapping CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2024-01-26 Naser-Aldin Lashgari, Nazanin Momeni Roudsari, Amirhossein Niknejad, Hedieh Sadat Shamsnia, Maryam Shayan, Leila Mohaghegh Shalmani, Saeideh Momtaz, Nima Rezaei, Amir Hossein Abdolghaffari
Background: Involvement of gastrointestinal inflammation in Parkinson’s disease (PD) pathogenesis and movement have progressively emerged. Inflammation is involved in the etiology of both PD and inflammatory bowel disease (IBD). Transformations in leucine-rich recurrent kinase 2 (LRRK2) are among the best hereditary supporters of IBD and PD. Elevated levels of LRRK2 have been reported in stimulated
-
Pharmacotherapy in SAH: Clinical Trial Lessons CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2024-01-21 Sotirios Apostolakis, Pantelis Stavrinou
: Subarachnoid Haemorrhage (SAH) is a medical emergency with potentially devastating outcomes. It is without doubt that over the past decades, there has been a radical change in the approach towards patients with SAH, both in terms of the surgical as well as of the pharmacological treatments offered. The present review aims to outline the principal data regarding the best practice in the pharmacotherapy
-
Role of Imaging Genetics in Alzheimer’s Disease: A Systematic Review and Current Update CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2024-01-21 Aakash Chhetri, Kashish Goel, Abhilash Ludhiadch, Paramdeep Singh, Anjana Munshi
Background: Alzheimer’s disease is a neurodegenerative disorder characterized by severe cognitive, behavioral, and psychological symptoms, such as dementia, cognitive decline, apathy, and depression. There are no accurate methods to diagnose the disease or proper therapeutic interventions to treat AD. Therefore, there is a need for novel diagnostic methods and markers to identify AD efficiently before
-
GFAP and UCHL1 in Non-traumatic SAH: The Story thus Far. A Systematic Review of the Literature CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2024-01-12 Filippos Psochias, Georgios Mavrovounis, George Stranjalis, Theodosis Kalamatianos
Objective:: Non-traumatic subarachnoid hemorrhage (SAH) is associated with a high percentage of misdiagnosis and poor prognosis. Biomarkers could be useful in the identification, treatment/management guidance, and outcome improvement of SAH patients. The current systematic review aims to investigate the potential role of biomarkers GFAP (Glial Fibrillary Acidic Protein) and UCH-L1 (Ubiquitin C-Terminal
-
Intrathecal Baclofen Infusion-Botulinum Toxin Combined Treatment Efficacy in the Management of Spasticity due to Cerebral Palsy CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2024-01-11 Riccardo Marvulli, Giuseppa Lagioia, Giancarlo Ianieri, Lucrezia Dell'Olio, Alessandra Zonno, Mariagrazia Riccardi, Rosa Bianca Sinisi, Laura Belinda Rizzo, Giacomo Farì, Marisa Megna, Maurizio Ranieri
Background: Cerebral Palsy (CP) is a group of permanent, but not unchanging, disorders of movement and/or posture and motor function, which are due to a non-progressive interference, lesion, or abnormality of the developing/immature brain. One clinical presentation is muscle spasticity, which leads to a significant impact on the individual’s functionality and quality of life. Spasticity treatment is
-
Anti-seizure Medications: Challenges and Opportunities CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2024-01-09 Neha Tandon, Milica Radosavljevic, Danijela Vucevic, Miroslav Radenkovic, Jasna Jancic, Janko Samardzic
: Epilepsy is a chronic neurological condition characterized by unprovoked, recurrent seizures. There are several types of epilepsy, and the cause of the condition can vary. Some cases of epilepsy have a genetic component, while others may be caused by brain injuries, infections, or other underlying conditions. Treatment for epilepsy typically involves anti-seizure medications (ASMs), although different
-
Nordihydroguaiaretic Acid Affects Undifferentiated and Differentiated Neuroblastoma Cells Differently through Mechanisms that Impact on Cell Viability CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2023-12-27 Patricia Ferrera, César Espino De la Fuente-Muñoz, Clorinda Arias
Aim: We aimed to investigate the mechanisms involved in the neurotoxic effects of NDGA on differentiated and undifferentiated human neuroblastoma cells (MSN), assessing cell viability, changes in the actin cytoskeleton, cell migration and the expression of the 5-LOX enzyme and the inhibitor of cell cycle progression p21WAF1/CIP1. Background: High expression and activity of the lipoxygenase enzyme (LOX)
-
Natural Compounds as Inhibitors of Aβ Peptide and Tau Aggregation CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2023-11-29 Kadja Luana Chagas Monteiro, Thiago Mendonça de Aquino, Edeildo Ferreira da Silva-Júnior
: Neurodegenerative conditions like Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) encompass disorders characterized by the degeneration of neurons in specific circumstances. The quest for novel agents to influence these diseases, particularly AD, has unearthed various natural compounds displaying multifaceted activities and diverse pharmacological mechanisms
-
Vasospasm in Pediatric Subarachnoid Hemorrhage CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2023-11-28 Ioannis Mavridis, Efstratios-Stylianos Pyrgelis, Eleni Agapiou, Jeries Assi
: Cerebral vasospasm (CV) is a common severe complication of subarachnoid hemorrhage (SAH), a severe type of intracranial bleeding that is uncommon in children. The purpose of this article is to review the current literature regarding this potentially devastating complication. CV may be asymptomatic and is less common in children compared to adults. Several molecular phenomena, including inflammatory
-
Intestinal Barrier Function and Neurodegenerative Disease CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2023-11-27 Shijing Wu, Liangfang Yang, Yiwei Fu, Zhimin Liao, De Cai, Zhou Liu
: Neurodegenerative diseases are caused by the loss of neurons and/or their myelin sheaths, which deteriorate over time and become dysfunctional. Alzheimer's disease, Parkinson's disease, and multiple sclerosis are among the most prominent neurodegenerative diseases that affect millions of older adults worldwide. Despite extensive research over several decades, controversies still surround the etiology
-
Transdermal Therapeutic Systems for the Treatment of Alzheimer's Disease: A Patent Review CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2023-11-22 Letícia Basso, Silvia Cristina Fagundes, Tatiana Staudt, Karini da Rosa, Elizane Langaro, Hamid Omidian, Charise Dallazem Bertol
Background: Two classes of medications are used to treat Alzheimer's disease (AD); donepezil, galantamine, and rivastigmine are acetylcholinesterase inhibitors, and memantine is a non-competitive antagonist of the N-methyl-D-aspartate receptor. Although these are typically taken orally, there are transdermal therapeutic systems (TTSs) commercially available for rivastigmine and donepezil. The transdermal
-
Metabolic Disorder Therapeutics and their Effects on Memory CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2023-11-06 Punita Agarwal, Faiz Khan, Sugato Banerjee
abstract: Diabetes is one of the major metabolic disorders of this era. It not only impacts a person's lifestyle but also has a long-term impact on the brain. It has a detrimental effect on a person's health when combined with hypertension and hyperlipidaemia. Several studies have suggested that the incidence of dementia is higher in people with metabolic syndrome. Investigations are underway to determine
-
The Essential Role of Astrocytes in Neurodegeneration and Neuroprotection CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2023-11-02 Federico López Couselo, Julieta Saba, Lila Carniglia, Daniela Durand, Mercedes Lasaga, Carla Caruso
abstract: Astrocytes are glial cells that perform several fundamental physiological functions within the brain. They can control neuronal activity and levels of ions and neurotransmitters, and release several factors that modulate the brain environment. Over the past few decades, our knowledge of astrocytes and their functions has rapidly evolved. Neurodegenerative diseases are characterized by selective
-
Circadian Rhythms and Sleep Disorders Associated to Major Depressive Disorder: Pathophysiology and Therapeutic Opportunities CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2023-10-27 Luana M. Manosso, Luciano A. Duarte, Nicoly S. Martinello, Gisiane B. Mathia, Gislaine Z. Réus
: Major depressive disorder (MDD) is a complex mood disorder. While much progress has been made in understanding the pathophysiology of MDD, no single mechanism can explain all facets of this disorder. Several studies show that disturbances in biological rhythms can lead to the development of MDD. Indeed, insomnia or hypersomnia are symptoms included in the MDD diagnostic criteria. Clinical studies
-
Artificial Intelligence in The Management of Neurodegenerative Disorders CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2023-10-19 Sanchit Dhankar, Somdutt Mujwar, Nitika Garg, Samrat Chauhan, Prerna Sharma, Satish Kumar Sharma, Mohammad Amjad Kamal, Dr. Nidhi Rani, Suresh Kumar, Monika Saini
: Neurodegenerative disorders are characterized by a gradual but irreversible loss of neurological function. The ability to detect and treat these conditions successfully is crucial for ensuring the best possible quality of life for people who suffer from them. The development of effective new methods for managing and treating neurodegenerative illnesses has been made possible by recent developments
-
Length of Survival, Outcome, and Potential Predictors in Poor-Grade Aneurysmal Subarachnoid Hemorrhage Patients Treated with Microsurgical Clipping CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2023-10-19 Xanthoula Lambrianou, Christos Tzerefos, Christina Arvaniti, Anastasia Tasiou, Kostas N. Fountas
Background: Poor-grade aneurysmal subarachnoid hemorrhage (aSAH) has been associated with severe morbidity and high mortality. It has been demonstrated that early intervention is of paramount importance. The aim of our study is to evaluate the functional outcome and the overall survival of early microsurgically treated patients. Material and Methods: Poor-grade aSAH patients admitted at our institution
-
The Effectiveness of Transcranial Magnetic Stimulation in Treating Apraxia CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2023-10-17 Asma Ruwaili, Rida Fatima, Amal Hussain, Mohammad Uzair, Turki Abualait, Kaleem Imdad, Shahid Bashir
: Apraxia can be detected when engaging in mental motor envisioning exercises. The nonverbal skills of manufacturing, representation, strategizing, arithmetic, visual sensitivity, and motor skills are all related to apraxia. Limb apraxia also negatively affects communication gestures and linguistic skills. The impairment of brain regions related to motion patterns is the primary cause of apraxia. People
-
Exerkines: A Crosstalk between Lactate Production, Exercise and Mental Health CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2023-10-16 Alberto Souza Sá Filho, Silvio Roberto Barsanulfo, Sara Socorro Faria, Pedro Augusto Inacio, Faranahz Ayatizadeh, Sérgio Machado
: Muscle skeletal striated cells secrete a wide range of proteins called myokines or “exerkines”, which in turn perform autocrine, paracrine, or endocrine functions. For being able to act in the communication between skeletal muscle, adipose tissue, and mainly the brain, exerkines play a prominent role and potential influence on health promotion. Furthermore, we detected in the literature that one
-
Role of Alpha-7-Nicotinic Acetylcholine Receptor in Alzheimer's Disease CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2023-10-16 Sushma Singh, Neetu Agrawal, Ahsas Goyal
: Alzheimer's disease (AD) is a neurodegenerative disorder affecting millions worldwide. One of the leading hypotheses for the underlying cause of AD is a reduction in nicotinic receptor levels in the brain. Among the nicotinic receptors, the alpha-7-nicotinic acetylcholine receptor (α7nAChR) has received particular attention due to its involvement in cognitive function.α7nAChR is a ligand-gated ion
-
Phosphodiesterase 2 and Its Isoform a as Therapeutic Targets in the Central Nervous System Disorders CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2023-10-15 Sanjay K. Metkar, Yuqing Yan, Yue Lu, Jianming Lu, Xiongwei Zhu, Fu Du, Ying Xu
: Cyclic adenosine monophosphates (cAMP) and cyclic guanosine monophosphate (cGMP) are two essential second messengers, which are hydrolyzed by phosphodiesterase's (PDEs), such as PDE-2. Pharmacological inhibition of PDE-2 (PDE2A) in the central nervous system improves cAMP and cGMP signaling, which controls downstream proteins related to neuropsychiatric, neurodegenerative, and neurodevelopmental
-
The Landscape of Randomized Clinical Trial Meta-analyses on Statins for Aneurysmal Subarachnoid Hemorrhage: A Scoping Review CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2023-10-15 Panagiotis Skouras, Theodosis Kalamatianos, Mariam Markouli, Angelos Karagiannis, Lampis C. Stavrinou
Introduction: Aneurysmal subarachnoid hemorrhage (aSAH) is a type of non-traumatic SAH that can have detrimental effects on the central nervous system, resulting in severe disability or death. Methods: Early nimodipine is currently the only strongly recommended pharmacological treatment that has shown efficacy in improving neurological/functional outcomes in aSAH patients. Whether statin treatment
-
Memory Reflections of the Microbiota-Gut and Oligodendrocyte Axis CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2023-10-15 Suman Kumar Ray, Sukhes Mukherjee
: Memory is the persisting consequence of cognitive activities instigated by and engrossed on exterior information from the environment and commenced by an intensive on internal mental representations. Establishing a gut-brain axis (GBA) in health and disease has recently brought the gut, the main portal of communication with the external environment, to the forefront of this interaction. Dietary stimuli
-
Role of Astrogliosis in the Pathogenesis of Parkinson’s Disease: Insights into Astrocytic Nrf2 Pathway as a Potential Therapeutic Target CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2023-10-09 Bharat Bhushan, Niraj Kumar Singh
:: Recently, Parkinson’s disease (PD) has become a remarkable burden on families and society with an acceleration of population aging having several pathological hallmarks such as dopaminergic neuronal loss of the substantia nigra pars compacta, α-synucleinopathy, neuroinflammation, autophagy, last but not the least astrogliosis. Astrocyte, star-shaped glial cells perform notable physiological functions
-
Montelukast Ameliorates Scopolamine-induced Alzheimer’s Disease: Role on Cholinergic Neurotransmission, Antioxidant Defence System, Neuroinflammation and Expression of BDNF CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2023-10-02 Bhavana Yerraguravagari, Naga Pavani Penchikala, Aravinda sai Kolusu, Grandhi Sandeep Ganesh, Prasad Konduri, Kumar V.S Nemmani, Pavan Kumar Samudrala
Background: Alzheimer's disease (AD) is an overwhelming neurodegenerative disease with progressive loss of memory. AD is characterized by the deposition of the senile plaques mainly composed of β-amyloid (Aβ) fragment, BDNF decline, Cholinergic system overactivity and neuroinflammation. Montelukast (MTK), a leukotriene receptor antagonist, showed astounding neuroprotective effects in a variety of neurodegenerative
-
Neuroprotection or Sex Bias: A Protective Response to Traumatic Brain Injury in the Females CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2023-09-27 Mohammad I. Yatoo, Ghaith A. Bahader, Shafayat A. Beigh, Adil M. Khan, Antonisamy William James, Maleha R. Asmi, Zahoor A. Shah
Traumatic brain injury (TBI) is a major healthcare problem and a common cause of mortality and morbidity. Clinical and preclinical research suggests sex-related differences in short- and longterm outcomes following TBI; however, males have been the main focus of TBI research. Females show a protective response against TBI. Female animals in preclinical studies and women in clinical trials have shown
-
Therapeutic Potential of Myricetin in the Treatment of Neurological, Neuropsychiatric, and Neurodegenerative Disorders CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2023-09-21 Neeraj Kumar Sethiya, Neha Ghiloria, Akanksha Srivastav, Dheeraj Bisht, Sushil Kumar Chaudhary, Vaibhav Walia, Md. Sabir Alam
Myricetin (MC), 3,5,7,3′,4′,5′-hexahydroxyflavone, chemically belongs to a flavonoid category known to confer antioxidant, antimicrobial, antidiabetic, and neuroprotective effects. MC is known to suppress the generation of Reactive Oxygen Species (ROS), lipid peroxidation (MDA), and inflammatory markers. It has been reported to improve insulin function in the human brain and periphery. Besides this
-
Role of BDNF signaling in the neuroprotective and memory-enhancing effects of flavonoids in Alzheimer’s Disease CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2023-09-13 Meysam Amidfar, Michelle Lima Garcez, Gholamreza Askari, Mohammad Bagherniya, Fariborz Khorvash, Sahar Golpour Hamedani, Jade de Oliveira
Introduction: Foods rich in flavonoids are associated with a reduced risk of various chronic diseases, including Alzheimer's disease (AD). In fact, growing evidence suggests that consuming flavonoid-rich foods can beneficially affect normal cognitive function. Animal models have shown that many flavonoids prevent the development of AD-like pathology and improve cognitive deficits. Result: Flavonoid-rich
-
Deciphering the Role of Peroxisome Proliferator-activated Receptor α and Phosphodiesterase Type 5 Targets in Alzheimer's Disease CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2023-09-06 Parnika M Sose, Pravin P Kale, Gaurav M Doshi
: The most prevalent cause of dementia is Alzheimer's disease (AD). Although the global AD rate is on a constant rise, medical research is yet to find a cure for this neurological condition. Current available therapeutic drugs for AD treatment only provide symptomatic alleviation. Therefore, it is essential to establish effective AD treatment strategies in addressing clinical needs. The development
-
Mycotoxins and Amyotrophic Lateral Sclerosis: Food Exposure, Nutritional Implications and Dietary Solutions CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2023-08-31 Umberto Manera, Enrico Matteoni, Antonio Canosa, Stefano Callegaro, Federico Casale, Daniela Marchis, Rosario Vasta, Cristina Moglia, Adriano Chiò, Andrea Calvo
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder determined by a combination of both genetic and environmental factors. Despite wide investigations, the role of chronic exposure to environmental pollutants is still rather unknown. Among natural toxins, the mycotoxins have received major attention only in the last few years, due to both technical and scientific achievements that allowed
-
Evolutionary Unmasking Resuscitative Therapeutics Potential of Centhaquin Citrate in Hypovolemic Shock CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2023-08-22 Ravinder Singh, Varinder Singh, Pratima Kumari, Namita Aggarwal, Muskaan Oberoi, Heena Khan, Thakur Gurjeet Singh
Hypovolemic shock (HS), a clinical condition of insufficient blood perfusion and oxygenation in body tissues, is associated with immense morbidity and mortality. Treatment approaches include fluid replacement and surgical repair of reversible causes of hemorrhage; however, they cause irreversible blood perfusion loss, systemic inflammation, multiple organ failure, and death. Centhaquin citrate (CC)
-
The number of antiseizure medications taken and not the lipid profile was associated with seizure control in adult patients with epilepsy CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2023-08-17 Vania Aparecida Leandro-Merhi, Glória Maria de Almeida Souza Tedrus, Giovanna Gigolotti Jacober de Moraes, Michele Novaes Ravelli
: Previous studies show changes in lipid metabolism in epilepsy. The aim of this study was to investigate the association between lipid profile and clinical variables in adult patients with epilepsy (APE). Seventy-two APE participated in this pilot study at an outpatient neurology service. The lipid profile (total cholesterol, low-density lipoprotein (LDL) cholesterol, very-low-density lipoproteins
-
Unraveling the Role of Neuroligin3 in Autism Spectrum Disorders: Pathophysiological Insights and Targeted Therapies CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2023-07-31 Fatima Azzahrae EL Yacoubi, Mohamed Oukabli, Azeddine Ibrahimi, Hassan Kisra, Mounia Bensaid
Autism Spectrum Disorder is a neurodevelopmental disorder characterized by impaired social and communication skills, repetitive behaviors, and/or restricted interests with a prevalence of as high as 1% of children. Autism spectrum has strongly associated with genetic factors and exhibits wide clinical and heterogeneous genetic architecture. Most genes associated with Autism are involved in neuronal
-
Towards a Systemic Concept of the Brain Ishemia Stroke: Monte Carlo Driven In Silico Model CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2023-07-20 Valentin V. Fursov, Alexander V. Ananiev, Dmitry A. Kuznetsov
Background: The work proposes a new mathematical model of dynamic processes of a typical spatially heterogeneous biological system, and sets and solves a mathematical problem of modeling the dynamics of the system of neurovascular units of the brain in conditions of ischemic stroke. There is a description of only a small number of mathematical models of stroke in the literature. This model is being
-
Oxidative Stress and Dopaminergic Metabolism: A Major PD Pathogenic Mechanism and Basis of Potential Antioxidant Therapies CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2023-07-18 Aamir Rasool, Robina Manzoor, Kaleem Ullah, Ramsha Afzal, Asad Ul-Haq, Hadia Imran, Imdad Kaleem, Tanveer Akhtar, Anum Farrukh, Sahir Hameed, Shahid Bashir
Reactive oxygen species (ROS)-induced oxidative stress triggers the vicious cycle leading to the degeneration of dopaminergic neurons in the nigra pars compacta. ROS produced during the metabolism of dopamine is immediately neutralized by the endogenous antioxidant defense system (EADS) under physiological conditions. Aging decreases the vigilance of EADS and makes the dopaminergic neurons more vulnerable
-
Casein Kinase 2 Affects Epilepsy by Regulating Ion Channels: A Potential Mechanism CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2023-07-12 Yan Liu, Di Xia, Lianmei Zhong, Ling Chen, Linming Zhang, Mingda Ai, Rong Mei, Ruijing Pang
Epilepsy, characterized by recurrent seizures and abnormal brain discharges, is the third most common chronic disorder of the Central Nervous System (CNS). Although significant progress has been made in the research on antiepileptic drugs (AEDs), approximately one-third of patients with epilepsy are refractory to these drugs. Thus, research on the pathogenesis of epilepsy is ongoing to find more effective
-
Navigated Transcranial Magnetic Stimulation (nTMS) based Preoperative Planning for Brain Tumor Treatment CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2023-07-07 Hammad Riaz, Mohammad Uzair, Muhammad Arshad, Ali Hamza, Nedal Bukhari, Faisal Azam, Shahid Bashir
Transcranial Magnetic Stimulation (TMS) is a non-invasive technique for analyzing the central and peripheral nervous system. TMS could be a powerful therapeutic technique for neurological disorders. TMS has also shown potential in treating various neurophysiological complications, such as depression, anxiety, and obsessive-compulsive disorders, without pain and analgesics. Despite advancements in diagnosis
-
Prevention of Parkinson’s Disease: From Risk Factors to Early Interventions CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2023-07-07 Ming Guan Ng, Brendan Jun Lam Chan, Rhun Yian Koh, Khuen Yen Ng, Soi Moi Chye
Parkinson’s disease (PD) is a debilitating neurological disorder characterized by progressively worsening motor dysfunction. Currently, available therapies merely alleviate symptoms, and there are no cures. Consequently, some researchers have now shifted their attention to identifying the modifiable risk factors of PD, with the intention of possibly implementing early interventions to prevent the development
-
The Peripheral Profile of the Chitinase 3-like-1 in Benign Multiple Sclerosis – A Single Centre’s Experience CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2023-07-07 Laura Barcutean, Adina Hutanu, Sebastian Andone, Smaranda Maier, Rodica Balasa
Background: A limited subgroup of multiple sclerosis (MS) patients present with a longterm disease evolution characterized by a limited disease progression, known as benign MS (BMS). Chitinase 3-like-1 (CHI3L1) levels are sensitive to inflammatory processes and may play a role in the pathogenesis of MS. In this observational, cross-sectional study, we aimed to evaluate the implications of serum CHI3L1
-
Lifestyle Modulators of Neuroplasticity in Parkinson’s Disease: Evidence in Human Neuroimaging Studies CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2023-07-05 Silvia Paola Caminiti, Silvia Gallo, Federico Menegon, Andrea Naldi, Cristoforo Comi, Giacomo Tondo
Parkinson’s disease (PD) is a neurodegenerative disease characterized by both motor and non-motor symptoms. A progressive neuronal loss and the consequent clinical impairment lead to deleterious effects on daily living and quality of life. Despite effective symptomatic therapeutic approaches, no disease-modifying therapies are currently available. Emerging evidence suggests that adopting a healthy
-
Flow diversion for the management of posterior circulation’s intracranial aneurysms CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2023-06-27 Panagiotis Papanagiotou, Antonis Adamou, Kirill Alektoroff, Maria Politi, Maria Alexandrou, Christian Roth
: The endovascular treatment of posterior circulation aneurysms, although challenging, has been well-established due to various factors that limit the surgical approach in most cases. Flow diversion has also been utilized in the treatment of such aneurysms, although its effectiveness and safety still require evaluation. Numerous studies have examined the outcomes and complication rates in patients
-
A Comprehensive Review of the Docking Studies of Chalcone for the Development of Selective MAO-B Inhibitors CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2023-06-26 Athulya Krishna, Sunil Kumar, Sachithra Thazhathuveedu Sudevan, Ashutosh Kumar Singh, Leena K. Pappachen, T.M. Rangarajan, Mohamed A. Abdelgawad, Bijo Mathew
Monoamine oxidase B is a crucial therapeutic target for neurodegenerative disorders like Alzheimer's and Parkinson's since they assist in disintegrating neurotransmitters such as dopamine in the brain. Pursuing efficacious monoamine oxidase B inhibitors is a hot topic, as contemporary therapeutic interventions have many shortcomings. Currently available FDA-approved monoamine oxidase inhibitors like
-
The Participation of Ca2+ Channels in Epilepsy: A Bibliometric Analysis of the Scientific Literature in Latin America CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2023-06-23 Carmen Rubio, Noel Gallardo, Vanessa Mena, Alonso Portilla, Moisés Rubio-Osornio
Background: Bibliometric analysis allows us to quantify and evaluate scientific activity, and it has become increasingly important in all areas of scientific literature. Thanks to these analyses, we can infer where science should put greater efforts into elucidating the underlying mechanisms of diseases that have yet to be fully described or investigated. Objective: This paper delves into published
-
Microarray-based Analysis of Differential Gene Expression Profile in Rotenone-induced Parkinson’s Disease Zebrafish Model CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2023-06-21 Yong Hui Nies, Mohamad Fairuz Yahaya, Wei Ling Lim, Seong Lin Teoh
Background & Objectives: Despite much clinical and laboratory research that has been performed to explore the mechanisms of Parkinson’s disease (PD), its pathogenesis remains elusive to date. Therefore, this study aimed to identify possible regulators of neurodegeneration by performing microarray analysis of the zebrafish PD model’s brain following rotenone exposure. Methods: A total of 36 adult zebrafish
-
The Effects and Mechanism of Scutellaria baicalensis Georgi Stems and Leaves Flavonoids on Myelin Sheath Degeneration Induced by Composite Aβ in Rats CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2023-06-19 Xu Congcong, Ye Yuanyuan, Li Caixia, Shang Yazhen
Background: Alzheimer's disease is a degenerative disease of the central nervous system, and its characteristic pathological changes are closely associated with Aβ deposition and neurofibrillary tangles. Many studies have found that malignant changes in the myelin sheath and oligodendrocyte (OL) are accompanied by the occurrence and development of AD. Therefore, any method that can resist myelin sheath
-
One-Trial Appetitive Learning Tasks for Drug Targeting CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2023-06-15 Robert Lalonde, Catherine Strazielle
One-trial appetitive learning developed from one-trial passive avoidance learning as a standard test of retrograde amnesia. It consists of one learning trial followed by a retention test, in which physiological manipulations are presented. As in passive avoidance learning, food- or waterdeprived rats or mice finding food or water inside an enclosure are vulnerable to the retrograde amnesia produced
-
Brain-Derived Neurotrophic Factor – The Protective Agent Against Neurological Disorders CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2023-06-15 Prathyusha Koyya, Ram Kumar Manthari, Santhi Latha Pandrangi
The burden of neurological illnesses on global health is significant. Our perception of the molecular and biological mechanisms underlying intellectual processing and behavior has significantly advanced over the last few decades, laying the groundwork for potential therapies for various neurodegenerative diseases. A growing body of literature reveals that most neurodegenerative diseases could be due
-
Evaluating the Potential of Green Light Exposure on Nociception-A Mini Review CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2023-06-15 Hammad Qaiser, Mohammad Uzair, Muhammad Arshad, Anessa Zafar, Shahid Bashir
The capacity of animals to react to unpleasant stimuli that might endanger their integrity is known as nociception. Pharmacological treatments do not show satisfactory results in response to nociception. In the recent era, light therapy emerged as a potential non-pharmacological approach for treating various diseases, including seasonal affective disorders, migraine, pain, and others. Evaluating the
-
New Insights into the Relationship between Nutrition and Neuroinflammation in Alzheimer's Disease: Preventive and Therapeutic Perspectives CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2023-06-13 Fabiola De Marchi, Francesca Vignaroli, Letizia Mazzini, Cristoforo Comi, Giacomo Tondo
Neurodegenerative diseases are progressive brain disorders characterized by inexorable synaptic dysfunction and neuronal loss. Since the most consistent risk factor for developing neurodegenerative diseases is aging, the prevalence of these disorders is intended to increase with increasing life expectancy. Alzheimer’s disease is the most common cause of neurodegenerative dementia, representing a significant
-
The Role of Non-coding RNAs in Alzheimer’s Disease: Pathogenesis, Novel Biomarkers, and Potential Therapeutic Targets CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2023-06-13 Othman Saleh, Khaled Albakri, Abdalrahmn Altiti, Iser Abutair, Suhaib Shalan, Omar Bassam Mohd, Ahmed Negida, Gohar Mushtaq, Mohammad A. Kamal
Long non-coding RNAs (IncRNAs) are regulatory RNA transcripts that have recently been associated with the onset of many neurodegenerative illnesses, including Alzheimer's disease (AD). Several IncRNAs have been found to be associated with AD pathophysiology, each with a distinct mechanism. In this review, we focused on the role of IncRNAs in the pathogenesis of AD and their potential as novel biomarkers
-
Therapeutic Viewpoint on Rat Models of Locomotion Abnormalities and Neurobiological Indicators in Parkinson's Disease CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2023-06-09 Rishabh Chaudhary, Randhir Singh
Background: Locomotion problems in Parkinson's syndrome are still a research and treatment difficulty. With the recent introduction of brain stimulation or neuromodulation equipment that is sufficient to monitor activity in the brain using electrodes placed on the scalp, new locomotion investigations in patients having the capacity to move freely have sprung up. Objective: This study aimed to find
-
The Use of Midazolam as an Antiseizure Medication in Neonatal Seizures: Single Center Experience and Literature Review CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2023-06-09 Ausilia Desiree Collotta, Raffaele Falsaperla, vincenzo sortino, simona domenica marino, Silvia marino, Francesco Pisani, Martino Ruggieri
Background: Existing therapeutic alternatives for neonatal crises have expanded in recent decades, but no consensus has been reached on protocols based on neonatal seizures. In particular, little is known about the use of midazolam in newborns. Aim: The aim of our study is to evaluate the response to midazolam, the appearance of side effects, and their impact on therapeutic decisions. Methods: This
-
Is There a Role of Vitamin D in Alzheimer’s Disease? CNS Neurol. Disord. Drug Targets (IF 3.0) Pub Date : 2023-06-08 Domenico Plantone, Matteo Pardini, Stefano Caneva, Nicola De Stefano
Alzheimer’s disease (AD) represents the most prevalent type of neurodegenerative dementia and the sixth leading cause of death worldwide. The so-called “non-calcemic actions” of vitamin D have been increasingly described, and its insufficiency has already been linked to the onset and progression of the main neurological diseases, including AD. Immune-mediated Aβ plaque’s phagocytosis and clearance